Towards new avenues in the management of lupus glomerulonephritis, Nature Reviews Rheumatology, vol.15, issue.4, pp.221-234, 2016. ,
DOI : 10.1177/0961203306071872
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis, Arthritis Care & Research, vol.63, issue.6, pp.797-808, 2012. ,
DOI : 10.1002/art.30293
Joint European League Against Rheumatism and European Renal Association???European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis, Annals of the Rheumatic Diseases, vol.71, issue.11, pp.1771-1782, 2012. ,
DOI : 10.1136/annrheumdis-2012-201940
Diagnosis and treatment of lupus nephritis, Consensus document from the systemic auto-immune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and Spanish Society of Nephrology (S.E.N.) ,
Lupus nephritis management guidelines compared, Nephrology Dialysis Transplantation, vol.31, issue.6, pp.904-913, 2016. ,
DOI : 10.1093/ndt/gfv102
Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis, Arthritis & Rheumatology, vol.35, issue.Suppl 2, pp.1432-1441, 2016. ,
DOI : 10.3899/jrheum.080214
Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus, Rheumatology, vol.53, issue.8, pp.1470-1476, 2014. ,
DOI : 10.1093/rheumatology/keu148
Lupus nephritis: A critical review, Autoimmun Rev, vol.12, issue.2, pp.174-94, 2012. ,
Treatment of severe lupus nephritis: the new horizon, Nature Reviews Nephrology, vol.59, issue.1, 2015. ,
DOI : 10.1038/nrrheum.2010.117
Updates on the Treatment of Lupus Nephritis, Journal of the American Society of Nephrology, vol.21, issue.12, pp.2028-2063, 2010. ,
DOI : 10.1681/ASN.2010050472
The frequency and outcome of lupus nephritis: results from an international inception cohort study, Rheumatology, vol.55, issue.2, pp.252-62, 2016. ,
DOI : 10.1093/rheumatology/kev311
The prevalence and incidence of biopsyproven lupus nephritis in the UK: Evidence of an ethnic gradient, Arthritis Rheum, 2006. ,
The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited, Journal of the American Society of Nephrology, vol.15, issue.2, pp.241-50, 2004. ,
DOI : 10.1097/01.ASN.0000108969.21691.5D
Kidney transplantation in patients with systemic lupus erythematosus, World Journal of Transplantation, vol.4, issue.3, p.176, 2014. ,
DOI : 10.5500/wjt.v4.i3.176
Long-term outcomes of end-stage kidney disease for patients with lupus nephritis, Kidney International, vol.89, issue.6, pp.1337-1382, 2016. ,
DOI : 10.1016/j.kint.2016.02.014
Update on Lupus Nephritis Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc -Eur Ren Assoc, Clin J Am Soc Nephrol CJASN, vol.1027, issue.8, pp.3248-54, 2012. ,
Towards new avenues in the management of lupus glomerulonephritis, Nature Reviews Rheumatology, vol.15, issue.4, pp.221-255, 2016. ,
DOI : 10.1177/0961203306071872
Mortality in Systemic Lupus Erythematosus: an Updated Review, Current Rheumatology Reports, vol.55, issue.1 ,
DOI : 10.1002/art.21695
The importance of glucocorticoid receptors in systemic lupus erythaematosus. A systematic review, ):21. 13. Bazsó A, 2015. ,
The history of pulse therapy in lupus nephritis Systemic lupus erythematosus diagnosis and management. Rheumatol Oxf Engl, Lupus Sci Med, vol.3, issue.16, 1976. ,
Synthetic pharmacotherapy for lupus nephritis, Expert Opinion on Pharmacotherapy, vol.33, issue.4, pp.1-12, 2017. ,
DOI : 10.1002/art.34359
Glucocorticoid use and abuse in SLE, Rheumatology, vol.51, issue.7 ,
DOI : 10.1093/rheumatology/ker410
URL : https://academic.oup.com/rheumatology/article-pdf/51/7/1145/5089377/ker410.pdf
Antiinflammatory Action of Glucocorticoids ??? New Mechanisms for Old Drugs, New England Journal of Medicine, vol.353, issue.16, pp.1711-1734, 2005. ,
DOI : 10.1056/NEJMra050541
The molecular basis for the effectiveness, toxicity, and resistance to glucocorticoids: focus on the treatment of rheumatoid arthritis, Scandinavian Journal of Rheumatology, vol.2001, issue.81, pp.14-21, 2005. ,
DOI : 10.1002/1097-4644(20010401)81:1<149::AID-JCB1031>3.0.CO;2-W
Past, present and future drug treatment for rheumatoid arthritis and systemic lupus erythematosus, Immunology and Cell Biology, vol.37, issue.5, pp.350-353, 2003. ,
DOI : 10.1016/S0165-2478(99)00025-5
URL : http://www.nature.com/icb/journal/v81/n5/pdf/icb200353a.pdf
Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens, Nature Reviews Immunology, vol.10, issue.4, pp.318-346, 2006. ,
DOI : 10.1164/ajrccm.161.1.9903137
Differential effects of corticosteroids during different stages of dendritic cell maturation, European Journal of Immunology, vol.30, issue.4, 2000. ,
DOI : 10.1002/(SICI)1521-4141(200004)30:4<1233::AID-IMMU1233>3.0.CO;2-F
A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1., Proceedings of the National Academy of Sciences, vol.89, issue.21, pp.9991-9996, 1992. ,
DOI : 10.1073/pnas.89.21.9991
Inhibition of VCAM-1 Expression in Human Bronchial Epithelial Cells by Glucocorticoids, American Journal of Respiratory Cell and Molecular Biology, vol.20, issue.4, pp.643-50, 1999. ,
DOI : 10.1165/ajrcmb.20.4.3265
Corticosteroids inhibit lymphocyte binding to endothelium and intercellular adhesion: an additional mechanism for their anti-inflammatory and immunosuppressive effect, J Immunol Baltim Md, vol.158, issue.10, pp.5007-5023, 1950. ,
Glucocorticoids inhibit chemokine generation by human eosinophils, Journal of Allergy and Clinical Immunology, vol.101, issue.1, pp.75-83, 1998. ,
DOI : 10.1016/S0091-6749(98)70196-4
Expression of monocyte chemotactic protein (MCP)-1, MCP-2, and MCP-3 by human airway smooth-muscle cells. Modulation by corticosteroids and T-helper 2 cytokines, Am J Respir Cell Mol Biol, 1999. ,
Glucocorticoid receptor in patients with lupus nephritis: relationship between receptor levels in mononuclear leukocytes and effect of glucocorticoid therapy, J Rheumatol, vol.19, issue.6, pp.878-83, 1992. ,
Negative Relationship Between Expression of Glucocorticoid Receptor ?? and Disease Activity: Glucocorticoid Treatment of Patients with Systemic Lupus Erythematosus, The Journal of Rheumatology, vol.37, issue.2, pp.316-337, 2010. ,
DOI : 10.3899/jrheum.090191
Association study of glucocorticoid receptor genetic polymorphisms with efficacy of glucocorticoids in systemic lupus erythematosus: A prospective cohort study, Autoimmunity, vol.94, issue.8, pp.531-537, 2013. ,
DOI : 10.2337/diabetes.51.10.3128
Glucocorticoid receptor action in beneficial and side effects of steroid therapy: Lessons from conditional knockout mice, Molecular and Cellular Endocrinology, vol.275, issue.1-2, pp.98-108, 2007. ,
DOI : 10.1016/j.mce.2007.05.009
URL : https://hal.archives-ouvertes.fr/hal-00531928
Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor, J Leukoc Biol, 2002. ,
Selective glucocorticoid receptor agonists (SEGRAs): Novel ligands with an improved therapeutic index, Molecular and Cellular Endocrinology, vol.275, issue.1-2, pp.109-126, 2007. ,
DOI : 10.1016/j.mce.2007.05.014
Optimised glucocorticoid therapy: the sharpening of an old spear, The Lancet, vol.365, issue.9461, pp.801-804, 2005. ,
DOI : 10.1016/S0140-6736(05)71005-9
Identification of Target Genes Involved in the Antiproliferative Effect of Glucocorticoids Reveals a Role for Nuclear Factor-??B Repression, Molecular Endocrinology, vol.19, issue.3, pp.632-675, 2005. ,
DOI : 10.1210/me.2004-0294
Quantitation of glucocorticoid receptor alpha and NF-??B pathway mRNA and its correlation with disease activity in rheumatoid arthritis patients, Genetics and Molecular Research, vol.9, issue.4, pp.2300-2310, 2010. ,
DOI : 10.4238/vol9-4gmr970
How glucocorticoid receptors modulate the activity of other transcription factors: A scope beyond tethering, Molecular and Cellular Endocrinology, vol.380, issue.1-2, pp.41-54, 2013. ,
DOI : 10.1016/j.mce.2012.12.014
Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists, Molecular and Cellular Endocrinology, vol.275, issue.1-2, pp.71-79, 2007. ,
DOI : 10.1016/j.mce.2007.05.019
URL : https://hal.archives-ouvertes.fr/hal-00531935
Glucocorticoids in the treatment of rheumatic diseases: An update on the mechanisms of action, Arthritis & Rheumatism, vol.48, issue.11, 2004. ,
DOI : 10.4049/jimmunol.171.6.3245
Rapid glucocorticoid effects on immune cells, Steroids, vol.67, issue.6, 2002. ,
DOI : 10.1016/S0039-128X(01)00171-4
Genomic and nongenomic effects of glucocorticoids, Nature Clinical Practice Rheumatology, vol.149, issue.10, pp.525-558, 2008. ,
DOI : 10.4049/jimmunol.171.6.3245
TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus, Nature, vol.203, issue.7300, pp.937-978, 2010. ,
DOI : 10.4049/jimmunol.174.9.5193
Immunosuppression by Glucocorticoids: Inhibition of NF-kappaB Activity Through Induction of IkappaB Sy nthesis, Science, vol.270, issue.5234, pp.286-90, 1995. ,
DOI : 10.1126/science.270.5234.286
Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology, Annals of the Rheumatic Diseases, vol.61, issue.8, pp.718-740, 2002. ,
DOI : 10.1136/ard.61.8.718
Therapeutic implications of non-genomic glucocorticoid activity, The Lancet, vol.356, issue.9224, pp.87-96, 2000. ,
DOI : 10.1016/S0140-6736(00)02463-6
New insights into the immunopathogenesis of systemic lupus erythematosus, Nature Reviews Rheumatology, vol.135, issue.12, pp.716-746 ,
DOI : 10.1016/j.jaci.2014.07.063
The role of dendritic cells in autoimmunity, Nature Reviews Immunology, vol.110, issue.8, pp.566-77, 2013. ,
DOI : 10.1073/pnas.1307569110
Type I interferons: crucial participants in disease amplification in autoimmunity, Nature Reviews Rheumatology, vol.3, issue.1, pp.40-49, 2010. ,
DOI : 10.1172/JCI23025
Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus, J Immunol Baltim Md, vol.163, issue.11, pp.6306-6319, 1950. ,
The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer, J Immunol Baltim Md, vol.165, issue.6, pp.3519-3545, 1950. ,
Induction of Dendritic Cell Differentiation by IFN-alpha in Systemic Lupus Erythematosus, Science, vol.294, issue.5546, pp.1540-1543, 2001. ,
DOI : 10.1126/science.1064890
TLR4 ligands induce IFN-alpha production by mouse conventional dendritic cells and human monocytes after IFNbeta priming, J Immunol Baltim Md, vol.182, issue.2, pp.820-828, 1950. ,
DOI : 10.4049/jimmunol.182.2.820
URL : http://www.jimmunol.org/content/jimmunol/182/2/820.full.pdf
Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials Available from Lupus nephritis management guidelines compared, Arthritis Res Ther Nephrol Dial Transplant, vol.1731, issue.16, pp.904-917, 2015. ,
Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis, Lupus, vol.78, issue.5, pp.628-661, 2010. ,
DOI : 10.1097/01.TP.0000140969.43761.1F
EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases, Annals of the Rheumatic Diseases, vol.327, issue.12, pp.1905-1918, 2013. ,
DOI : 10.1136/bmj.327.7429.1459
American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis, Arthritis Care & Research, vol.63, issue.6, pp.797-808 ,
DOI : 10.1002/art.30293
Joint European League Against Rheumatism and European Renal Association???European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis, Annals of the Rheumatic Diseases, vol.71, issue.11, pp.1771-82, 2017. ,
DOI : 10.1136/annrheumdis-2012-201940
EULAR evidencebased recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases, ald_21_pnds_lupus_web.pdf 61, pp.1560-1567, 2007. ,
Long-term complications of past glucocorticoid use, Autoimmunity Reviews, vol.12, issue.5 ,
DOI : 10.1016/j.autrev.2012.12.002
Damage in systemic lupus erythematosus and its association with corticosteroids, Arthritis & Rheumatism, vol.13, issue.8, pp.1801-1809, 2000. ,
DOI : 10.2165/00002018-199513010-00001
Corticosteroids in Lupus, Rheumatic Disease Clinics of North America, vol.42, issue.1, 2016. ,
DOI : 10.1016/j.rdc.2015.08.007
Systemic lupus erythematosus, bone health, and osteoporosis, Current Opinion in Endocrinology, Diabetes and Obesity, vol.22, issue.6, pp.422-453 ,
DOI : 10.1097/MED.0000000000000197
Risk factors for osteoporosis and fragility fractures in patients with systemic lupus erythematosus Prevalence of fractures in women with rheumatoid arthritis and/or systemic lupus erythematosus on chronic glucocorticoid therapy, Lupus Sci Med. BMC Musculoskelet Disord, vol.316, issue.1, pp.98-68300, 2015. ,
High-Dose Corticosteroid Use and Risk of Hip Osteonecrosis: Meta-Analysis and Systematic Literature Review, The Journal of Arthroplasty, vol.30, issue.9, 2015. ,
DOI : 10.1016/j.arth.2015.03.036
Predictors of the first cardiovascular event in patients with systemic lupus erythematosus -a prospective cohort study Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study, Arthritis Res Ther. Arthritis Res Ther, vol.1114, issue.62, p.46, 2009. ,
Impact of Chronic Glucocorticoid Treatment on Cardiovascular Risk Profile in Patients with Systemic Lupus Erythematosus, JCR: Journal of Clinical Rheumatology, vol.22, issue.1, pp.8-12, 2016. ,
DOI : 10.1097/RHU.0000000000000335
Risk factors in cardiovascular disease in systemic lupus erythematosus, Curr Cardiol Rev. 2013 Feb, vol.19, issue.1, pp.15-24 ,
Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis, The American Journal of Medicine, vol.96, issue.3, pp.254-263, 1994. ,
DOI : 10.1016/0002-9343(94)90151-1
Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort, Lupus, vol.27, issue.13, pp.170-175, 2000. ,
DOI : 10.1016/0167-5273(90)90294-F
Prevention and management of co-morbidities in SLE. Presse Médicale, pp.187-95, 2014. ,
Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies, Lupus, vol.32, issue.2, pp.1286-94, 2013. ,
DOI : 10.1177/0961203309106921
Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis, Best Practice & Research Clinical Rheumatology, vol.16, issue.2, pp.281-91, 2002. ,
DOI : 10.1053/berh.2001.0226
Infection in systemic lupus erythematosus. Médecine Mal Infect Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years, Rheumatol Oxf Engl, vol.37, issue.12, pp.792-797, 2007. ,
Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort, Arthritis Care & Research, vol.30, issue.1, pp.132-139 ,
DOI : 10.1177/0961203309359289
Immunopathogenesis and spectrum of infections in systemiclupus erythematosus. Semin Arthritis Rheum, pp.318-354, 1996. ,
Infections as triggers and complications of systemic lupus erythematosus, Autoimmunity Reviews, vol.8, issue.1, pp.24-32, 2008. ,
DOI : 10.1016/j.autrev.2008.07.019
Infectious complications in SLE after immunosuppressive therapies, Current Opinion in Rheumatology, vol.15, issue.5, pp.528-562, 2003. ,
DOI : 10.1097/00002281-200309000-00002
Serious Infections Among Adult Medicaid Beneficiaries With Systemic Lupus Erythematosus and Lupus Nephritis, Arthritis & Rheumatology, vol.67, issue.6, pp.1577-85 ,
DOI : 10.1002/art.38981
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446132/pdf
The nature and outcome of infection in systemic lupus erythematosus, Lupus, vol.35, issue.4, pp.234-243, 2002. ,
DOI : 10.2169/internalmedicine.35.629
INFECTIONS ASSOCIATED WITH STEROID USE, Infectious Disease Clinics of North America, vol.15, issue.2, pp.423-455, 2001. ,
DOI : 10.1016/S0891-5520(05)70154-9
INFECTIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS, Infectious Disease Clinics of North America, vol.15, issue.2, pp.335-61, 2001. ,
DOI : 10.1016/S0891-5520(05)70149-5
Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus, Annals of the Rheumatic Diseases, vol.60, issue.12 ,
DOI : 10.1136/ard.60.12.1141
The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus, Arthritis & Rheumatism, vol.36, issue.3, 1996. ,
DOI : 10.1002/art.1780390303
Accrual of organ damage over time in patients with systemic lupus erythematosus, J Rheumatol, vol.30, issue.9, pp.1955-1964, 2003. ,
Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus, Rheumatology, vol.53, issue.8, pp.1470-1476, 2014. ,
DOI : 10.1093/rheumatology/keu148
Towards treating lupus nephritis without oral steroids: a dreamcome-true? Ann Rheum Dis, pp.1271-1273, 2013. ,
DOI : 10.1136/annrheumdis-2013-203205
URL : http://ard.bmj.com/content/annrheumdis/72/8/1271.full.pdf
Predictors of corticosteroid tapering in SLE patients: the Hopkins Lupus Cohort, Lupus, vol.30, issue.7, pp.697-701, 2013. ,
DOI : 10.1002/art.10364
Prednisone in lupus nephritis: how much is enough? Autoimmun Rev, Feb, vol.13, issue.2, pp.206-220, 2014. ,
DOI : 10.1016/j.autrev.2013.10.013
The Steroids In the Maintenance of remission of Proliferative Lupus nephritis (SIMPL) pilot trial Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis - Full Text View -ClinicalTrials.gov [Internet]. [cited 2017 Feb 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT01773616 100. Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus -Full Text View -ClinicalTrials, Can J Kidney Health Dis. Ann Rheum Dis, vol.172, issue.8, pp.30-981280, 2013. ,
BC) contre 86% (CC), p <0,001, respectivement à 6 et 12 mois Les patients de CC ont plus fréquemment atteint une RC (HR ajusté 3 Le nombre de boli de méthylprednisolone était associé à la RC Les patients dans le CC ont un risque plus faible d'effets secondaires liés aux GCs, pp.0-001 ,